The EHEC disaster – opportunities for the early treatment of acutely ill patients using an natural preparation

Reports on the therapeutic options for the treatment of hemorrhagic diarrhoea and the prophylaxis of life-threatening complications like HUS as a result of the infection with „Killer Coli“, as enterohaemorrhagic Escherichia coli (EHEC) is termed sometimes, are often evidence of a degree of uncertainty and above all a lack of knowledge with regards to proven and tested therapeutic treatments.

In the context of the epidemic of severe EHEC cases which occured in Bavaria, Germany in the 1990s, we carried out a placebo-controlled clinical study of a colostrum preparation (Lactobin®) on 30 acutely ill children at the University Hospital Wuerzburg (I.Huppertz et al - J Pediatr Gastroenterol Nutr 1999; 29:452-456). The patients treated with Lactobin® experienced a normalisation of the encreased defecation rates within a shortest possible time period (statistically highly relevant compared with the placebo group) and an increased elimination of EHEC.

Even though preliminary investigations indicate that the current epidemic deals with a new variant of EHEC , a treatment attempt with40g Lactobin® (now Lactobin N®) per day would be recommendable in suspected cases of EHEC infection (severe diarrhoea lasting more than 24 hours with more than 4 possibly hemorrhagic stools per day) on the basis of the data from Wuerzburg. Any risk to provoke HUS through this regimen (as this is discussed in the medicinal literature concerning the use of antibiotics in EHEC infected patients), the preparation is well-tolerated (exception: lactose intolerance) and can be taken over longer periods. (Manufacturer: Dr Wolz Zell GmbH in Geisenheim, info@wolz.de).

Author: MD Reinhard Lissner

Dr. Wolz Zell GmbH was founded in 1969 by Siegfried Wolz in Geisenheim and specialises in the development of functional food supplements on the basis of cellular respiration.
Dr. Wolz Zell GmbH manufactures only products with ingredients that have been scientifically researched and which have proven effects. All the products contain natural, biological ingredients which are derived exclusively from natural sources. They are manufactured in a demanding process, taking particular care to ensure good bioavailability of the biological substances. During the last couple of years a new cooperation with clinical pharmacologists and immunologists has occurred with the developement of LACTOBIN® N.

Dr. Wolz Zell GmbH
Marienthaler Str. 3
65366 Geisenheim
Germany

Press contact: Herr Dr. M. Oldhaver
Fon: +49 (0)6722 - 5610 - 0
Fax: +49 (0)6722 - 5610 - 20
info@wolz.de

This release was published on openPR.